Summit Therapeutics Inc. Deferred Tax Liabilities, Intangible Assets
Summit Therapeutics Inc. (SMMT) had Deferred Tax Liabilities, Intangible Assets of $0 as of 2022-12-31, per its 10-K filed 2023-03-09.
Discontinued › Notes › Income Taxes › Components of Deferred Tax Assets and Liabilities › Deferred Tax Liabilities, Net › Deferred Tax Liabilities, Gross
us-gaap:DeferredTaxLiabilitiesGoodwillAndIntangibleAssetsIntangibleAssets · last filed 2023-03-09
- 2022-12-31: Deferred Tax Liabilities, Intangible Assets $0.00.
- 2021-12-31: Deferred Tax Liabilities, Intangible Assets $2.60M.
- 2020-12-31: Deferred Tax Liabilities, Intangible Assets $2.19M.
- 2019-12-31: Deferred Tax Liabilities, Intangible Assets $2.06M.
| Period end | Deferred Tax Liabilities, Intangible Assets |
|---|---|
| 2022-12-31 | $0.00 10-K · filed 2023-03-09 |
| 2021-12-31 | $2.60M 10-K · filed 2023-03-09 |
| 2020-12-31 | $2.19M 10-K/A · filed 2022-12-21 |
| 2019-12-31 | $2.06M 10-K · filed 2021-03-31 |
| 2019-01-31 | $2.20M 8-K · filed 2020-09-29 |
| 2018-01-31 | $3.37M 8-K · filed 2020-09-29 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| BridgeBio Pharma, Inc. (BBIO) | United States | $12.947B | -20.72 |
| CORCEPT THERAPEUTICS INC (CORT) | United States | $12.804B | 169.10 |
| BIOMARIN PHARMACEUTICAL INC (BMRN) | United States | $11.879B | 151.80 |
| MADRIGAL PHARMACEUTICALS, INC. (MDGL) | United States | $11.859B | -38.17 |
| Elanco Animal Health Inc (ELAN) | United States | $11.177B | -61.80 |
| Jazz Pharmaceuticals plc (JAZZ) | $15.333B | 16.07 | |
| Axsome Therapeutics, Inc. (AXSM) | United States | $10.274B | -66.82 |
| ARROWHEAD PHARMACEUTICALS, INC. (ARWR) | United States | $9.331B | -42.28 |
| CYTOKINETICS INC (CYTK) | United States | $9.130B | -11.86 |
| Protagonist Therapeutics, Inc (PTGX) | United States | $8.883B | 95.52 |